Compare MPWR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPWR | BIIB |
|---|---|---|
| Founded | 1997 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 27.1B |
| IPO Year | 2004 | 1996 |
| Metric | MPWR | BIIB |
|---|---|---|
| Price | $1,069.49 | $187.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 27 |
| Target Price | ★ $1,122.93 | $195.00 |
| AVG Volume (30 Days) | 442.0K | ★ 721.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.86 | 8.79 |
| Revenue | $333,067,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $23.74 | N/A |
| Revenue Next Year | $17.55 | N/A |
| P/E Ratio | $82.35 | ★ $21.75 |
| Revenue Growth | ★ 17.89 | 2.22 |
| 52 Week Low | $438.86 | $110.04 |
| 52 Week High | $1,256.22 | $202.41 |
| Indicator | MPWR | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 51.01 |
| Support Level | $899.99 | $170.99 |
| Resistance Level | $1,123.38 | $191.60 |
| Average True Range (ATR) | 36.52 | 4.17 |
| MACD | 1.46 | 0.34 |
| Stochastic Oscillator | 46.65 | 52.17 |
Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).